Joinn Laboratories(China)Co (603127) - Total Liabilities

Latest as of March 2026: CN¥1.48 Billion CNY ≈ $216.53 Million USD

Based on the latest financial reports, Joinn Laboratories(China)Co (603127) has total liabilities worth CN¥1.48 Billion CNY (≈ $216.53 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Joinn Laboratories(China)Co - Total Liabilities Trend (2012–2025)

This chart illustrates how Joinn Laboratories(China)Co's total liabilities have evolved over time, based on quarterly financial data. See 603127 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Joinn Laboratories(China)Co Competitors by Total Liabilities

The table below lists competitors of Joinn Laboratories(China)Co ranked by their total liabilities.

Company Country Total Liabilities
Financière Amuse TopCo SAS
ST:ASMDEE-B
Sweden Skr1.39 Billion
Liechtensteinische Landesbank Aktiengesellschaft
STU:LLS1
Germany €25.96 Billion
Schneider National Inc
NYSE:SNDR
USA $1.96 Billion
The Chefs Warehouse Inc
NASDAQ:CHEF
USA $1.38 Billion
Ningbo Jintian Copper Group Co Ltd
SHG:601609
China CN¥18.37 Billion
WNS Holdings Ltd
NYSE:WNS
USA $771.00 Million
Lifestance Health Group Inc
NASDAQ:LFST
USA $668.47 Million
Avista Corporation
NYSE:AVA
USA $5.63 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Joinn Laboratories(China)Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Joinn Laboratories(China)Co market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.02 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.17 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.15 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Joinn Laboratories(China)Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Joinn Laboratories(China)Co (2012–2025)

The table below shows the annual total liabilities of Joinn Laboratories(China)Co from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥1.36 Billion
≈ $198.51 Million
+3.01%
2024-12-31 CN¥1.32 Billion
≈ $192.71 Million
-24.58%
2023-12-31 CN¥1.75 Billion
≈ $255.51 Million
-19.66%
2022-12-31 CN¥2.17 Billion
≈ $318.03 Million
+56.06%
2021-12-31 CN¥1.39 Billion
≈ $203.79 Million
+57.60%
2020-12-31 CN¥883.66 Million
≈ $129.31 Million
+49.63%
2019-12-31 CN¥590.57 Million
≈ $86.42 Million
+20.55%
2018-12-31 CN¥489.89 Million
≈ $71.69 Million
+27.88%
2017-12-31 CN¥383.08 Million
≈ $56.06 Million
+13.72%
2016-12-31 CN¥336.88 Million
≈ $49.30 Million
+23.11%
2015-12-31 CN¥273.64 Million
≈ $40.04 Million
-6.49%
2014-12-31 CN¥292.63 Million
≈ $42.82 Million
+13.33%
2013-12-31 CN¥258.21 Million
≈ $37.78 Million
-8.04%
2012-12-31 CN¥280.79 Million
≈ $41.09 Million
--

About Joinn Laboratories(China)Co

SHG:603127 China Diagnostics & Research
Market Cap
$3.29 Billion
CN¥22.48 Billion CNY
Market Cap Rank
#4757 Global
#858 in China
Share Price
CN¥35.66
Change (1 day)
+9.99%
52-Week Range
CN¥18.72 - CN¥43.01
All Time High
CN¥175.47
About

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more